1. Cadonilimab plus chemotherapy significantly improved progression-free survival in patients with persistent, recurrent, or metastatic cervical cancer. 2. Common grade ...
1. Patients in the MGT group reported a significantly greater progression-free survival than those in the standard platinum-based chemotherapy group. ...
1. The Atezolizumab group demonstrated significantly greater progression-free and overall survival among patients with metastatic, persistent, or recurrent cervical cancer. ...
1. The Atezolizumab group demonstrated significantly greater progression-free and overall survival among patients with metastatic, persistent, or recurrent cervical cancer. ...
Click to read this study in NEJM. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed ...
1. Patients receiving pembrolizumab with or without platinum-based chemotherapy experienced longer progression-free and overall survival than the placebo group. 2. ...
1. Enfortumab vedotin showed improved overall survival when compared to chemotherapy in patients with previously treated advanced urothelial carcinoma. 2. ...
1. Median overall survival in the nivolumab plus ipilimumab group (18.1 months) was substantially greater than in the chemotherapy group ...
1. Among patients with platinum-sensitive recurrent ovarian cancer, those who received the PARP inhibitor niraparib demonstrated significantly increased progression-free survival ...
1. Oxaliplatin plus S-1 was non-inferior in terms of overall survival and progression free survival when compared to cisplatin plus ...
